Trial Profile
A Phase 2 Study of MLN0128 (TAK-228) in Patients With Advanced Non-Small Cell Lung Cancers Harboring NFE2L2 and KEAP1 Mutations
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 18 Oct 2022
Price :
$35
*
At a glance
- Drugs Sapanisertib (Primary)
- Indications Lung cancer; Non-small cell lung cancer; Squamous cell cancer
- Focus Pharmacogenomic; Therapeutic Use
- 11 Oct 2022 Results of efficacy, published in the Journal of Thoracic Oncology
- 19 Feb 2021 Status changed from active, no longer recruiting to completed.
- 17 Oct 2020 Planned primary completion date changed from 1 Dec 2020 to 1 Feb 2021.